（文章来源：证券日报） 证券日报网讯国科恒泰9月23日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东人数 为17660户。 ...

Core Insights - The company held an online performance briefing on September 17, 2025, with active participation from investors discussing business development and market trends [1][2] Business and Market Development Highlights - The global high-value medical consumables market is projected to reach $347.8 billion by 2031, with a compound annual growth rate (CAGR) of 8.4% from 2025 to 2031. Despite challenges such as rising raw material prices, product innovation remains a core focus. In China, factors like an aging population will drive demand for high-value medical consumables, indicating a broad market potential [3] Logistics and Supply Chain Advantages - As of June 30, 2025, the company operates 111 branches and subsidiaries across 31 provinces, cities, and autonomous regions in China. Its 2-hour delivery radius covers over 80% of tertiary hospitals nationwide, achieving 80,000 surgical setups in the first half of 2025. The establishment of 9 third-party warehouses in 8 cities enhances supply chain efficiency [4] Information Technology Leadership - The company has developed a mature information system utilizing cloud computing, featuring four supporting middle-platform architectures. It has independently developed core operational modules for business visibility and traceability, meeting various stakeholder needs. Additionally, the company collaborates with regulatory bodies to promote compliance in the industry [5] "JuXieTong" Initiative - The "JuXieTong" platform provides channel marketing and comprehensive supply chain solutions for manufacturers, addressing challenges such as recruitment difficulties. It supports fully automated business scenarios and leverages new internet technologies to create standardized business middle platforms, enhancing supply chain efficiency [6] Financial Performance in H1 2025 - In the face of market changes, the company optimized its product structure, achieving revenue of 3.679 billion yuan, a slight increase of 0.54% year-on-year. Net profit reached 52.1 million yuan, with net cash flow from operating activities amounting to 387 million yuan, reflecting a year-on-year growth of 11.21%. The company demonstrates a strong development trend in the high-value medical consumables market, supported by advantages in logistics and information technology [7]

Market Overview - The global high-value medical consumables market is projected to reach $347.8 billion by 2031, with a compound annual growth rate (CAGR) of 8.4% from 2025 to 2031 [1] - The Chinese market is under pressure due to accelerated volume-based procurement and price reductions, leading to a slowdown in overall industry growth [1][2] - By the end of 2024, China's medical device market is expected to reach approximately ¥1,063.8 billion, with a growth rate of about 3% from 2025 to 2030 [6][7] Company Operations - As of June 30, 2025, the company operates 111 subsidiaries across 31 provinces, covering over 80% of tertiary hospitals within a 2-hour delivery radius [2][13] - The company achieved 80,000 surgical setups in the first half of 2025 [2][13] - The company has established a public bonded warehouse in Tianjin, which allows for deferred tax payments and reduces operational costs for medical device companies [8] Digital Transformation - The company has developed a mature information management system, integrating cloud computing, distributed storage, and AI technologies to enhance supply chain efficiency [3][14] - The "Juxietong" product offers a comprehensive digital solution for manufacturers, addressing challenges in marketing, inventory management, and compliance [11][12] Financial Performance - In the first half of 2025, the company reported revenue of ¥3.679 billion, a slight increase of 0.54% year-on-year, with a net profit of ¥52.1 million [10][19] - The net cash flow from operating activities reached ¥387 million, reflecting an increase of 11.21% compared to the previous year [10][19] Risk Management and Market Strategy - The company has implemented a comprehensive risk control system to manage major contracts and projects, ensuring compliance and operational stability [16] - The company emphasizes value management and strategic resource allocation to enhance investor confidence and long-term returns [9][17] Industry Collaboration - The company has established partnerships with renowned medical device manufacturers, covering key areas such as orthopedics, cardiology, and neurosurgery [17]

证券日报网讯国科恒泰（301370）9月16日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东人数为17602户。 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-061 国科恒泰（北京）医疗科技股份有限公司 关于举行 2025 年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日在巨潮资讯网披露《2025 年半年度报告》及《2025 年半年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 9 月 17 日（星期三）15:00-16:00 在"价值在线"（www.ir-online.cn）举办 公司 2025 年半年度网上业绩说明会，与投资者进行沟通和交流，广泛听取投资者 的意见和建议。现将有关安排公告如下： 公司董事长刘冰先生，总经理、董事肖薇女士，独立董事姜涟先生，副总经理、 财务总监吴锦洪先生，副总经理费海鹏先生，副总经理、董事会秘书王小蓓女士。 如遇特殊情况，参会人员可能进行调整。 三、投资者参会方式 投 资 者 可 于 2025 年 9 月 17 日 （ 星 期 三 ） 15:0 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐人名称：长城证券股份有限公司 | 被保荐公司简称：国科恒泰 | | --- | --- | | 保荐代表人姓名：张涛 | 联系电话：0755-83516222 | | 保荐代表人姓名：李宛真 | 联系电话：0755-83516222 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 管理制度、内控制度、内部审计制度、关联交易 | 是 | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露文件 | 是 | | 一致 | ...

本公司及董事会全体成员保证信息披露的内容与信息披露义务人提供的信 息一致。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"或"国科恒泰"） 于 2025 年 5 月 8 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《关于公司 股东减持股份的预披露公告》（公告编号：2025-026）。 国科恒泰（北京）医疗科技股份有限公司 关于股东减持股份计划时间届满暨实施情况的公告 股东国科嘉和（北京）投资管理有限公司—苏州国丰鼎嘉创业投资合伙企业 （有限合伙）、西藏国科鼎奕投资中心（有限合伙）、宁波梅山保税港区国科瑞 鼎创业投资合伙企业（有限合伙）、国科金源（北京）投资管理有限公司—北京 国科嘉和金源投资基金中心（有限合伙）保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301370 证券简称：国科恒泰 公告编号：2025-060 公司股东国科嘉和（北京）投资管理有限公司—苏州国丰鼎嘉创业投资合伙企 业（有限合伙）（以下简称"国丰鼎嘉"）计划以集中竞价或大宗交易方式合计减 持公司股份不超过 6,911,501 股，减持比例不超过公司总股本的 ...

Core Viewpoint - Guoke Hengtai (301370) reported mixed financial results for the first half of 2025, with a slight increase in total revenue but a significant decline in net profit compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 reached 3.679 billion yuan, a year-on-year increase of 0.54% [1] - Net profit attributable to shareholders was 52.0954 million yuan, down 17.2% year-on-year [1] - In Q2 2025, total revenue was 1.94 billion yuan, a decrease of 0.22% year-on-year, while net profit for the quarter rose by 72.87% to 61.0479 million yuan [1] Key Financial Ratios - Gross margin was 10.16%, a decrease of 1.39% year-on-year [1] - Net margin was 1.5%, down 16.3% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 283 million yuan, accounting for 7.7% of revenue, an increase of 1.13% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents increased by 13.49% to 616 million yuan [1] - Accounts receivable decreased by 15.93% to 1.52 billion yuan, but still represented 1163.25% of net profit [1][2] - Interest-bearing liabilities decreased by 5.68% to 1.203 billion yuan [1] Shareholder Metrics - Earnings per share (EPS) was 0.11 yuan, down 15.38% year-on-year [1] - Book value per share increased by 3.41% to 5.29 yuan [1] - Operating cash flow per share was 0.82 yuan, an increase of 11.21% year-on-year [1] Business Model Insights - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors [2] - Cash flow status is a concern, with cash and cash equivalents covering only 37.21% of current liabilities [2]

Group 1 - The company Guoke Hengtai (SZ 301370) announced the convening of its 43rd board meeting on August 27, 2025, to review the semi-annual report for 2025 [1] - For the first half of 2025, the revenue composition of Guoke Hengtai was as follows: vascular interventional treatment materials accounted for 71.09%, other products 14.58%, non-vascular interventional treatment materials 5.27%, orthopedic implant materials 5.12%, and oral products 2.25% [1]

Group 1 - The company announced the acquisition of 40% equity in Liaoning Guoke Hengtai Medical Technology Co., Ltd. from Shenyang Qianfu Yu Trading Partnership, which will result in the company holding 100% of the equity after the acquisition [1] - The initial valuation of the equity asset is set at 3.7658 million yuan, with the final price not exceeding the assessment results provided by the evaluation agency and the results filed with the state-owned property management authority [1] - The board of directors approved the acquisition without the need for a shareholders' meeting, indicating that the decision falls within the board's authority [1]